Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: poly C effects on natural killer function.
Considerable interest has been focused on the use of interferon (IFN) and IFN-inducers as antineoplastic agents in humans. The current report will focus on the effect of intravesical administration of Poly I: Poly C on NK activity in patients with TCC of the urinary bladder. NK cytotoxicity was measured in 14 patients with primary TCC, 8 patients received Poly I: Poly C and 5 other patients received intravesical thiotepa. Blood samples were obtained prior to and 48 h following each drug treatment. A variation in the initial NK level determined prior to treatment was observed in the different TCC patients: 5 patients treated with Poly I: Poly C and 5 patients treated with thiotepa exhibited low NK activity prior to treatment, whereas the other 3 patients who were treated with Poly I: Poly C had high initial NK levels. Following drug treatment it was shown that a significant elevation in the NK cytotoxicity was only observed in patients treated by intravesical Poly I: Poly C who had low NK activity prior to treatment. No such effect was observed in patients treated with thiotepa or in patients treated with Poly I: Poly C who exhibited a high NK activity prior to treatment.
Moroz
C
C
Kupfer
B
B
Lindner
A
A
Many
M
M
D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007167:Immunotherapy; D066298:In Vitro Techniques; D007372:Interferons / Q000097:blood; D007694:Killer Cells, Natural / Q000276:immunology*; D008875:Middle Aged; D011070:Poly I-C / Q000627:therapeutic use*; D013852:Thiotepa / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D007372:Interferons; D013852:Thiotepa; D011070:Poly I-C